Cleveland BioLabs Stock Forecast, Price & News

Wall Street analysts have given Cleveland BioLabs a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cleveland BioLabs wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Cleveland BioLabs saw a increase in short interest in May. As of May 28th, there was short interest totaling 30,100 shares, an increase of 21.4% from the May 13th total of 24,800 shares. Based on an average daily trading volume, of 122,100 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.4% of the company's stock are short sold.
View Cleveland BioLabs' Short Interest.

Cleveland BioLabs is scheduled to release its next quarterly earnings announcement on Friday, June 18th 2021.
View our earnings forecast for Cleveland BioLabs.

Cleveland BioLabs, Inc. (NASDAQ:CBLI) announced its quarterly earnings data on Friday, May, 15th. The biotechnology company reported ($0.05) EPS for the quarter. The biotechnology company had revenue of $0.16 million for the quarter. Cleveland BioLabs had a negative trailing twelve-month return on equity of 42.74% and a negative net margin of 382.26%.
View Cleveland BioLabs' earnings history.

Cleveland BioLabs' stock was trading at $3.15 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CBLI shares have increased by 85.1% and is now trading at $5.83.
View which stocks have been most impacted by COVID-19.

Some companies that are related to Cleveland BioLabs include Immutep (IMMP), Citius Pharmaceuticals (CTXR), Cerecor (CERC), RedHill Biopharma (RDHL), Trevena (TRVN), Theratechnologies (THTX), Mustang Bio (MBIO), Frequency Therapeutics (FREQ), CymaBay Therapeutics (CBAY), Immunic (IMUX), Aeglea BioTherapeutics (AGLE), Arbutus Biopharma (ABUS), Iterum Therapeutics (ITRM), Sernova (SEOVF) and CorMedix (CRMD).
View all of CBLI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cleveland BioLabs investors own include iBio (IBIO), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Novavax (NVAX), Biocept (BIOC) and Co-Diagnostics (CODX).

Cleveland BioLabs trades on the NASDAQ under the ticker symbol "CBLI."

Cleveland BioLabs' stock is owned by a variety of retail and institutional investors. Top institutional investors include Morgan Stanley (1.40%), Renaissance Technologies LLC (0.84%), Geode Capital Management LLC (0.29%), ARS Investment Partners LLC (0.24%), Citadel Advisors LLC (0.24%) and Citadel Advisors LLC (0.24%).
View institutional ownership trends for Cleveland BioLabs.

CBLI stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for Cleveland BioLabs or view top insider-selling stocks.

CBLI stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, ARS Investment Partners LLC, Cambridge Investment Research Advisors Inc., Geode Capital Management LLC, Citadel Advisors LLC, Citadel Advisors LLC, and Northern Trust Corp.
View insider buying and selling activity for Cleveland BioLabs or or view top insider-buying stocks.

Shares of CBLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CBLI stock can currently be purchased for approximately $5.83.

Cleveland BioLabs has a market capitalization of $90.19 million and generates $260,000.00 in revenue each year.

Cleveland BioLabs employs 2 workers across the globe.

The official website for Cleveland BioLabs is www.cbiolabs.com.

Cleveland BioLabs is headquartered at 73 HIGH STREET, BUFFALO NY, 14203.

Cleveland BioLabs' mailing address is 73 HIGH STREET, BUFFALO NY, 14203. The biotechnology company can be reached via phone at 716-849-6810 or via email at [email protected]